A retrospective analysis of BCOR-immunohistochemistry positive uterine sarcomas: Clinical features and survival
Anbarasan Sekar, Bharat Rekhi, Jaya Ghosh, Santosh Menon, Omshree Shetty, Kedar Deodhar, Sushmita Rath, Neha Mittal, Anuradha Mehta, Seema Gulia, Amita Maheshwari, Supriya Chopra, Sudeep GuptaABSTRACT
Introduction:
BCOR-immunohistochemistry positive uterine sarcomas are rare mesenchymal tumors. They are clinically aggressive with a poor prognosis, and there is limited data on their clinicopathological features and treatment outcomes.
Methods:
In this study, we retrospectively analyzed 12 patients with BCOR-immunohistochemistry positive uterine sarcomas treated between 2021 and 2023, reviewing their clinical, pathological, immunohistochemical, and treatment data.
Results:
Majority of patients presented at advanced stages, with a median tumor size of 7.9 cm. The median progression-free survival was 7.7 (95%CI: 0–26.51) months, and overall survival was 17.9 (95% CI: 2.10–33.6) months. BCOR and cyclin D1 immunostaining served as useful adjuncts in pathological characterization; however, this cohort likely represents a heterogeneous collection of high-grade endometrial stromal sarcomas (HG-ESS) rather than a biologically homogeneous BCOR-altered group. Despite a multimodal treatment approach, clinical outcomes remained poor.
Conclusion:
BCOR-immunohistochemistry positive uterine sarcomas exhibit an aggressive course and limited response to current treatment paradigms. Incorporating BCOR immunostaining into the diagnostic workflow aids in initial characterization, but our findings underscore the critical need for comprehensive molecular profiling to accurately classify these heterogeneous tumors.